key: cord-0903705-yfztqy4z
authors: Sharma, Madhu; Gorstein, Samuel; Aldrich, Margaret L.; Hsu, Daphne T.; Choueiter, Nadine F.
title: Reversible Myocardial Injury Associated with SARS-CoV-2 in an Infant
date: 2020-10-12
journal: JACC Case Rep
DOI: 10.1016/j.jaccas.2020.09.031
sha: d3309a492269d2be7293acf6b65c707216d3ccf6
doc_id: 903705
cord_uid: yfztqy4z

Coronavirus disease 2019 (COVID-19) is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and has been associated with myocardial dysfunction and heart failure in adult patients. We report a case of reversible myocardial injury and heart failure in an infant with SARS-CoV-2 infection.

A 2-month old infant presented with an episode of choking and cyanosis after feeding.

There was no history of fever, cough, upper respiratory tract infection symptoms, diarrhea, vomiting or decreased oral intake prior to the initial presentation. On arrival of EMS, the patient had a pulse but poor respiratory effort and was treated with oxygen and bag mask ventilation. On arrival to the emergency department, non-rebreather mask ventilation (15L/min, 80% FiO 2 ) was initiated. On arrival to the pediatric intensive care unit, initial exam revealed a heart rate of 170 beats/minute, respiratory rate of 70 breaths/minute, a blood pressure of 66/36 mmHg and an oxygen saturation of 98%. The weight and height were at 66 th and 90 th percentile for corrected gestational age, respectively. The exam was significant for a 3/6 holosystolic murmur at the apex radiating to the axilla, liver was palpable 2-3 centimeters below the costal margin and the extremities were cool with 3-4 seconds capillary refill. Initial arterial blood gas was significant for mild metabolic acidosis with a lactate of 2.9 mmol/L ( Table 1) . On the first day of illness (DOI-1), pertinent laboratory data showed lymphopenia (2.1K/µL), elevated Troponin-T (TnT) 0.16 ng/mL (normal < 0.1 ng/mL) and N-terminal pro-B Natriuretic Peptide (NT-proBNP) 15000 pg/mL (normal < 450 pg/mL). The C-Reactive Protein (CRP) was normal. There were mild elevations in liver function tests, D-dimer and interleukin-6 levels. Initial assay for SARS- The patient was born at 33 weeks requiring a 3-week stay in the neonatal intensive care unit with one week of nasal continuous positive airway pressure support.

Given the initial presentation, ECG findings, troponin and NT pro-BNP elevation, the differential diagnosis at presentation included primary acute myocardial injury due to the viral infection versus an underlying dilated cardiomyopathy with heart failure symptoms exacerbated by the viral infection and ischemic dilated cardiomyopathy secondary to anomalous left coronary artery. There were no other cardiac abnormalities or pericardial effusion. Multiplex viral panel PCR to rule out other viral etiologies for acute myocarditis was negative.

Patient required fluid resuscitation and inotropic support for hypotension and mechanical ventilation for respiratory failure. On DOI-4, after obtaining approval for compassionate use, the patient was started on remdesivir, a nucleotide analogue prodrug that inhibits viral RNA polymerases which was continued for 10 days. Intravenous antibiotics, vancomycin and ceftriaxone were started to cover for possible superinfections until the blood culture showed no growth (DOI 1-4). The infant was extubated to non-invasive ventilation (NIV) on DOI-6. On DOI-8, the infant developed acute respiratory distress requiring re-intubation. TnT, pro-BNP, C-J o u r n a l P r e -p r o o f reactive protein and D-dimer increased. LV size, ventricular function and MR remained unchanged. On DOI-8 IV methylprednisolone at 2mg/kg/day was started. D-dimer increased to 9.78 µg/ml on DOI-10 (Table 1 ) and low molecular heparin was initiated at a therapeutic dose with a goal anti Xa level 0.6-1. The patient was extubated on DOI-14 to NIV support. TnT, pro-NT BNP and CRP decreased from DOI 8-14. Figure 3A shows the trend of selected laboratory values. LV size and function normalized (EF 58%) by DOI-14 and MR remained severe which subsequently improved. Milrinone was discontinued on DOI-16 and he did not require oral heart failure therapies. Figure 3B shows the trend of LV size and function over the course of illness.

The earliest reports of SARS-CoV-2 from China indicated the presence of myocardial injury in a subset of patients. In a cohort of 416 adult patients hospitalized with confirmed COVID-19, 20% had evidence of myocardial injury defined as serum cardiac biomarkers (high sensitivity TnT) above the 99th-percentile upper reference limit, regardless of new abnormalities in ECG or on echocardiography (1). Guo et al reported a slightly higher incidence (28%) of myocardial injury as indicated by elevated TnT levels in hospitalized patients with confirmed COVID-19 resulting in cardiac dysfunction and arrhythmia (2) . Both studies showed that older patients with pre-existing cardiovascular disease were at a higher risk of myocardial injury and at a higher mortality risk.

Most children with SARS-CoV-2 infection are either asymptomatic or have mild symptoms (3, 4) . We report a case of reversible myocardial injury and acute decompensated heart failure associated with documented SARS-CoV-2 infection in an infant. Echocardiographic evaluation demonstrated normal coronary artery origin and flow. The infant's presentation was atypical for a dilated cardiomyopathy because of the absence of a prior history of respiratory J o u r n a l P r e -p r o o f illnesses or poor feeding and the infant's normal height and weight-for-age z-scores (5) . The absence of significant LV dilation commonly seen in pediatric patients presenting with dilated cardiomyopathy was also atypical (6). Normalization of LV size and function within two weeks of presentation argues strongly for a reversible acute myocardial injury associated with SARS-CoV-2.

The presentation and clinical course of this patient mirrors four case reports of acute myocardial injury reported in adult patients with COVID-19 (7-10). All four cases presented with severe LV dysfunction, and elevated cardiac biomarkers (TnT, pro-NT BNP), which subsequently normalized. One 63-year-old patient required extracorporeal membrane oxygenation support and had normalization of his LVEF from 32% to 68% but died at DOI-36 (7) . Three patients survived and had normalization of LV systolic function. Cardiac magnetic resonance imaging was performed in two patients and demonstrated myocardial edema and a non-ischemic pattern of late gadolinium enhancement consistent with acute myocarditis (9,10).

Coronary angiography was normal in two patients with ST segment elevation on ECG and regional wall motion abnormality (8, 9) .

At the time of this submission, the patient has recovered and discharged home on no oral heart failure therapy with a close follow-up. The left ventricular size and systolic function have remained normal and the mitral regurgitation has resolved.

Acute myocardial injury as an atypical presentation of SARS-CoV-2 infection is currently being recognized in adult population. Our case highlights the potential for myocardial involvement in infants with SARS-CoV-2 infection.

Learning Objective 1) To be able to make a differential diagnosis of left ventricular dysfunction in infancy.

2) To understand the importance of testing for SARS-CoV-2 in children presenting with signs and symptoms of heart failure and LV dysfunction during the pandemic. 

Association of cardiac injury with mortality in hospitalized patients with COVID-19 inWuhan, China. JAMA Cardiol

Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19)

Epidemiological characteristics of 2143 pediatric patients with 2019 coronavirus disease in China

Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang, China: an observational cohort study

Abdominal complaints as a common first presentation of heart failure in adolescents with dilated cardiomyopathy

Incidence, Causes, and Outcomes of Dilated Cardiomyopathy in Children

First case of COVID-19 complicated with fulminant myocarditis: a case report and insights

Cardiac involvement in a patient with coronavirus disease 2019 (COVID-19)

Plasma, Interleukin-6 (IL-6), pg/ml <14.8 42 9.9